Daily Roundup

DXB.ASX RRL.ASX HGO.ASX LTP.ASX CYM.ASX

Dimerix bolsters pipeline and secures funding runway

Dimerix Limited is making significant moves to strengthen its position in the kidney disease space. The clinical-stage biotech company has acquired DMX-652, a Phase 2-ready asset for acute kidney injury from Mission Therapeutics. The selective USP30 inhibitor demonstrated a strong safety profile in its Phase 1 trial with no serious adverse events, and comes with an FDA-approved Phase 2 protocol and sufficient pharmaceutical-grade drug product ready to go. This acquisition complements Dimerix's ongoing Phase 3 trial for DMX-200 in focal segmental glomerulosclerosis, creating a more diversified pipeline focused on rare kidney diseases.

To support this expansion, Dimerix has secured AU$10 million in non-dilutive funding from SKIPTAN Pty Ltd, an associate of a substantial shareholder. The loan facility will cover commercial manufacturing of DMX-200, expanded access programs, and the Phase 2 trial launch for DMX-652. The company is now funded through completion of both the ACTION3 Phase 3 trial and the DMX-652 Phase 2 trial, with negotiations underway for an additional AU$40 million to extend the runway further.

Gold miners chart growth paths

Regis Resources has outlined an optimistic outlook for FY27, guiding for group gold production of 360-400 koz with Duketon expected to deliver higher output than FY26, particularly in the second half. The company plans to invest $250-270 million in growth capital at Duketon alongside $80-90 million for exploration. The McPhillamys project spend has also been increased to support a Final Investment Decision in the first half of 2028.

Hillgrove Resources is taking its own growth step with Board approval of the Emily Star development, a third underground mining front at the Kanmantoo Copper Mine. Drilling has confirmed geological continuity with no material geotechnical risks identified. The project carries a capital requirement of $20-22 million, with $6.5-7.5 million to be spent in the second half of 2026. Stoping is scheduled to commence in H2 2027, and the company plans to fund the development from operating cashflows. This approval raises Hillgrove's 2026 major capital guidance to $15-17 million.

Looking ahead, Hillgrove is also proposing a name change to Kantra Copper Limited and a 15-to-1 share consolidation to better reflect its copper focus and place the share price within a more conventional range. Shareholders will vote on these changes at a General Meeting scheduled for 17 August 2026.

Cyprium nears copper production restart

Cyprium Metals is entering the final stretch of its Phase 1 Copper Cathode Restart project at the Nifty Copper Complex. The company has commissioned a new acid terminal, with sulphuric acid deliveries to Nifty having recommenced. Site infrastructure work packages are advancing toward practical completion, and the company is targeting copper cathode production commencement in the September Quarter 2026. Leach solution recovery circuits are advancing toward commissioning, and hydro-testing on surface and injection leach programs on the heap leach have begun. The company has also appointed Richard Holmes as Chief Development Officer and Christofer Catania as Chief Technology Officer. Cyprium remains well-funded with A$68.5 million in cash at quarter-end.

LTR Pharma advances U.S. commercialization

LTR Pharma has executed a definitive Telehealth Distribution Agreement with Shed Holdings LLC, converting a previously announced binding term sheet into a comprehensive commercial agreement. Shed, a leading U.S. direct-to-consumer telehealth platform, will commercialize ROXUS through its dedicated men's health platform Mavrox and its own site. The company has committed to supporting delivery of at least 150,000 ROXUS units in the first 12 months following Commercial Launch. ROXUS is already featured on the Mavrox platform with a patient waitlist established, as the parties progress toward Commercial Launch.